LBA6 Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801)
S. Patel, Megan Othus, Víctor M. Prieto, M.C. Lowe, Elizabeth I. Buchbinder, Yuanbin Chen, John Hyngstrom, Christopher D. Lao, T-G. Truong, Shruti Chandra, Kari Kendra, Craig Devoe, A. Hedge, Ankit Mangla, Elad Sharon, Larissa A. Korde, James J. Moon, Vernon K. Sondak, A. Ribas
Topics & Concepts
MedicinePembrolizumabMelanomaAdjuvant therapyRandomized controlled trialClinical endpointInternal medicineSurgeryIpilimumabAdjuvantRandomizationOncologyRadiation therapyChemotherapyCancerImmunotherapyCancer researchCAR-T cell therapy researchCutaneous Melanoma Detection and ManagementCancer Immunotherapy and Biomarkers